Reassessment of the new diagnostic thresholds for gestational diabetes mellitus: an opportunity for improvement

Abstract

Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annuallyTO THE EDITOR: Patients with BRAF-mutated metastatic melanoma benefit greatly from the novel BRAF inhibitor dabrafenib and the checkpoint inhibitor ipilimumab, recently listed under the Australian Pharmaceutical Benefits Scheme (PBS). Dabrafenib results in rapid responses; but the cancer later adapts, and patients relapse rapidly. Conversely, ipilimumab slowly reactivates anticancer immunity, meaningfully improving long-term survival (up to around 20% at 5 years).